Allergan plc (AGN - Free Report) and partner Molecular Partners announced that the filings for their long-acting anti-VEGF product, abicipar pegol, developed for the treatment of age-related neovascular macular degeneration (nAMD), has been accepted for review by regulatory authorities in the United States and Europe.
While the FDA has accepted a biologics license application (BLA), the European Medicines Agency (EMA) has validated a marketing authorization application (MAA) for abicipar pegol. While the FDA is expected to give its decision in mid-2020, the same from EMA is expected in the second half of 2020.
The BLA and MAA filings were based on two phase III studies — SEQUOIA and CEDAR — evaluating abicipar compared with Novartis (NVS - Free Report) /Roche’s (RHHBY - Free Report) Lucentis (ranibizumab) in treatment-naïve patients with nAMD. Data from the studies demonstrated that treatment with six or eight injections of abicipar resulted in similar efficacy for the primary endpoint (proportion of treated patients achieving stable vision at week 52) compared to 13 injections for Lucentis.
Allergan’s share price has risen 22.7% this year so far against the industry’s decrease of 6.5%.
Please note that Regeneron Pharmaceuticals' (REGN - Free Report) blockbuster anti-VEGF drug Eylea (aflibercept) Injection is another popular drug approved to treat patients with nAMD. However, abicipar, with its quarterly dosing regimens, has the potential to reduce patient burden by lowering the frequency of injections while maintaining vision gains.
In April, Allergan announced data from another study on abicipar, MAPLE, a 28-week open-label study which used a modified manufacturing process to test an optimized 12-week formulation of abicipar in nAMD patients. Following the improved manufacturing process, it was observed that the incidence of intraocular inflammation (IOI) in the study was lower than SEQUOIA and CEDAR studies. In the MAPLE study, the reported incidence of IOI was 8.9%, which was less than around 15% observed in the SEQUOIA and CEDAR studies. If abicipar pegol is later approved as a fixed 12- week anti-VEGF treatment for nAMD based on MAPLE data, it will reduce the treatment burden for these patients.
Allergan currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>